Cases
NOTICE OF PENDENCY OF CLASS ACTION: Instadose Pharma Corp.
Securities Class Action
Overview
Overview
- Date:
- 11/16/2023
- Company Name:
- Instadose Pharma Corp.
- Stock Symbol:
- INSD
- Status:
- Pending
Instadose Securities Litigation
The information below relates to the action titled DeLuca v. Instadose Pharma Corp., et al., Case No. 2:21-cv-00675 (JKW)(RJK) (the “Action”) pending in the United States District Court for the Eastern District of Virginia.
The information contained on this web page is only a summary of information presented in more detail in the Notice of Pendency of Class Action (the “Notice”), which you can access by clicking here. Because this website is just a summary, you should review the Notice for additional details.
The purpose of the website is to inform you of a class action lawsuit that is now pending in the Court under the above caption (the “Action”) against Instadose Pharma Corp. (“Instadose” or the “Company”) and the Company’s former Chief Executive Officer Terry Wilshire (together, the “Defendants”). The Action has been certified by the Court to proceed as a class action on behalf of the Class defined below.
All persons and entities that purchased or otherwise acquired publicly traded Instadose securities from July 14, 2021, through November 24, 2021, both dates inclusive.
If you are a member of the Class, your legal rights will be affected whether you act or do not act. Please read the Notice carefully to fully understand your rights and options.
Please Note: This Action is currently ongoing. No court has made a ruling on the merits of the allegations asserted against Defendants in the Action or on Defendants’ denials and defenses. There is no judgment, settlement, or monetary recovery at this time, and there is no guarantee there will be any recovery. Defendants were served with the Complaint but failed to answer the Complaint and/or make an appearance. Default was entered against Defendants on August 25, 2022.
If you have questions, you may call RG/2 Claims Administration LLC at (866) 742-4955, or e-mail info@rg2claims.com.
The information contained on this web page is only a summary of information presented in more detail in the Notice of Pendency of Class Action (the “Notice”), which you can access by clicking here. Because this website is just a summary, you should review the Notice for additional details.
The purpose of the website is to inform you of a class action lawsuit that is now pending in the Court under the above caption (the “Action”) against Instadose Pharma Corp. (“Instadose” or the “Company”) and the Company’s former Chief Executive Officer Terry Wilshire (together, the “Defendants”). The Action has been certified by the Court to proceed as a class action on behalf of the Class defined below.
All persons and entities that purchased or otherwise acquired publicly traded Instadose securities from July 14, 2021, through November 24, 2021, both dates inclusive.
If you are a member of the Class, your legal rights will be affected whether you act or do not act. Please read the Notice carefully to fully understand your rights and options.
Please Note: This Action is currently ongoing. No court has made a ruling on the merits of the allegations asserted against Defendants in the Action or on Defendants’ denials and defenses. There is no judgment, settlement, or monetary recovery at this time, and there is no guarantee there will be any recovery. Defendants were served with the Complaint but failed to answer the Complaint and/or make an appearance. Default was entered against Defendants on August 25, 2022.
If you have questions, you may call RG/2 Claims Administration LLC at (866) 742-4955, or e-mail info@rg2claims.com.
WHAT ARE MY OPTIONS?
DO NOTHING: If you do nothing, and you are a member of the Class, you will stay in the Class. It will cost you nothing. If you do nothing and are a Class Member, you will be legally bound by all past, present, and future orders and judgments in this Action, whether favorable or unfavorable. At the end of the case, you may receive money or other benefits as may be awarded as a result of collection of monies after entry of a default judgment, as the result of a trial, or as a result of a settlement reached between the Class Representatives and Defendants, or you may receive nothing. However, if you remain a member of the Class, you may not pursue a lawsuit on your own behalf with regard to any of the issues in this Action.
EXCLUDE YOURSELF FROM THE CLASS BY FEBRUARY 14, 2024: If you choose to be excluded from the Class, you will not be bound by any past, present, or future orders and judgments in this Action, nor will you be eligible to share in any recovery that might be obtained in this Action. You will retain any rights you have, individually, if any, to sue Defendants separately in another lawsuit and bring the same legal claims that are part of this lawsuit. Please note, if you choose to exclude yourself from the Class, you may be subject to a statute of limitations and statute of repose, which set deadlines for filing the lawsuit within a certain period of time and which could foreclose certain or all claims. Please refer to paragraph Nos. 5 and 6 on pages 4-5 of the Notice if you would like to be excluded from the Class.